藥品和生物技術的選擇權和評估交易（2016-2024）

本報告深入了解和分析公司如何以及為何進行選擇權和評估交易。

本報告提供了2016年至2024年選擇權和評估交易的詳細資訊。

此報告提供了各方之間宣布的選擇權/評估交易的付款條款。這些資料提供了有關支付條款和其他交易條款的寶貴見解。

了解潛在合作夥伴談判條款的彈性，並深入了解談判過程，以了解條款談判期間的預期結果。許多小型企業會要求提供付款條件的詳細信息，但在包括付款方式和權利如何轉讓時，細節是關鍵。

本報告提供了自2016年以來宣布的期權/評估交易的完整列表，目前協議案件/合作夥伴資料庫中記錄的內容，並包括可用的財務條款，以及公司及其合作夥伴向證券交易委員會提交的實際許可協議文件的線上副本的連結。

主要優點

本報告為讀者提供了以下主要好處：

• 了解2016年以來的交易完成趨勢
• 查看選擇權和評估交易
• 基準分析：確定交易的市場價值
• 財務狀況
• 交易清單：依公司名稱（A-Z）、依治療領域、依技術類型
• 主要交易（金額基礎）
• 最活躍的交易者
• 每筆交易的資產識別和交易條件
• 取得合約文件：深入了解交易結構
• 實質審查：評估擬議交易條款對合作夥伴公司的適用性
• 節省數百小時的研究時間

調查範圍

• 本報告目的是詳細了解世界領先的生物製藥公司的選擇權/估值趨勢和交易結構。

此報告包含以下資訊：

• 生物製藥產業選擇權和評估交易的趨勢
• 選擇權/評估交易架構：概述
• 製藥和生技產業的選擇權和評估交易記錄列表
• 主要選擇權和評估交易（金額基礎）
• 最活躍的選擇權和評估交易者
• 用於選項和評估的主要合作夥伴資源

此報告列出了可獲得資訊的交易：

• 依公司名稱（A-Z）
• 依交易金額
• 依治療領域
• 依技術類型
• 每個交易標題都透過網路連結連結到實際交易記錄的線上版本。
• 此報告提供了對選擇權和評估合約的可用合約文件的全面存取。

透過分析合約協議，實質審查可以：

• 授予和選擇了哪些權利？
• 合約授予了哪些權利？
• 授予哪些專有權？
• 合約的付款結構是怎樣的？
• 如何審核銷售和付款？
• 合約期限是多久？
• 合約的主要條款是如何定義的？
• 如何對待和擁有知識產權？
• 誰負責商業化？
• 誰負責開發、供應和製造？
• 如何管理保密和發布？
• 如何解決爭議？
• 什麼情況下可以取消合約？
• 如果所有者發生變化會怎樣？
• 已商定何種類型的分授權或分包條款？
• 公司需要哪些樣板條款？
• 哪些樣板條款會根據合作夥伴和交易類型的不同而有所不同？
• 每家公司都主張合約法中的哪一個管轄權？

目錄

執行摘要

第1章 簡介

第2章 選項與評估趨勢

• 簡介
• 定義選擇權和評估交易
• 選擇權和評估交易的趨勢（自2016年以來）
  • 選擇權/評估交易：依年份（2016-2024年）
  • 選擇權/評量交易：依開發階段（2016-2024年）
  • 選擇權/評估交易：依產業（2016-2024年）
  • 選擇權/評估交易：依治療領域（2016-2024年）
  • 選擇權/評估交易：依技術類型（2016-2024年）
  • 選擇權/評估交易：針對最活躍的公司（2016-2024年）
• 簽訂選擇權/評估合約的原因
• 未來選擇權與評估交易

第3章 選擇權與評估交易結構概述

• 簡介
• 選項/評估結構

第4章 主要選擇權及評估交易

• 簡介
• 主要選擇權和評估交易（金額基礎）

第5章 25 位最活躍的選擇權和評估交易商

• 簡介
• 前 25 位最活躍的選擇權和評估交易商（進行交易的公司）

第6章 選擇權和評估交易清單（包括合約細節）

• 簡介
• 選擇權與評估交易合約（2016-2024年）
• 交易列表
• 交易清單：選擇權/評估交易，依公司名稱（A-Z）
• 交易清單：選擇權/評估交易，依治療領域
• 交易清單：選擇權/評估交易，依技術類型

關於Wildwood Ventures

• 目前的合作關係
• 當前合約
• Current Partnering 發布的最新報告標題

Option and Evaluation Deals in Pharmaceuticals and Biotechnology provides a detailed understanding and analysis of how and why companies enter option and evaluation deals.

Fully revised and updated, the report provides details of option and evaluation deals from 2016 to 2024.

The report provides access to option and evaluation deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of option and evaluation deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual option and evaluation contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of option and evaluation dealmaking and business activities.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview and analysis of the trends in option and evaluation as well as a discussion on the merits of the type of deal.

Chapter 3 provides an overview of the structure of option and evaluation deals.

Chapter 4 provides a review of the leading option and evaluation deals since 2016. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive listing of the top 25 most active option and evaluation dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.

Chapter 6 provides a comprehensive and detailed review of option and evaluation deals organized by company A-Z, therapy, technology and industry type signed and announced since 2016 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the option and evaluation deal.

The deal directory includes a comprehensive listing of all option and evaluation deals announced since 2016. Each listing is organized as a deal directory by company A-Z, therapeutic area and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.

The report also includes numerous table and figures that illustrate the trends and activities in option and evaluation dealmaking since 2016.

In conclusion, this report provides everything a prospective dealmaker needs to know about option and evaluation alliances.

Key benefits

Option and Evaluation Deals in Pharmaceuticals and Biotechnology provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse option and evaluation deals
• Benchmark analysis - identify market value of transactions
• Financials terms
• Directory of deals by company A-Z, therapy focus and technology type
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Option and Evaluation Deals in Pharmaceuticals and Biotechnology is intended to provide the reader with an in-depth understanding of the option and evaluation trends and structure of deals entered into by leading biopharma companies worldwide.

Option and Evaluation Deals in Pharmaceuticals and Biotechnology includes:

• Trends in option and evaluation dealmaking in the biopharma industry
• Overview of option and evaluation deal structure
• Directory of option and evaluation deal records covering pharmaceutical and biotechnology
• The leading option and evaluation deals by value
• Most active option and evaluation dealmakers
• The leading option and evaluation partnering resources

In Option and Evaluation Deals in Pharmaceuticals and Biotechnology, the available deals are listed by:

• Company A-Z
• Headline value
• Therapeutic area
• Technology type
• Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
• Option and Evaluation Deals in Pharmaceuticals and Biotechnology provides comprehensive access to available records for option and evaluation deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the rights granted or optioned?
• What rights are granted by the agreement?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are intellectual property rights handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in option and evaluation dealmaking

• 2.1. Introduction
• 2.2. Definition of option and evaluation deal
• 2.3. Trends in option and evaluation deals since 2016
  • 2.3.1. Option and evaluation dealmaking by year, 2016-2024
  • 2.3.2. Option and evaluation dealmaking by phase of development, 2016-2024
  • 2.3.3. Option and evaluation dealmaking by industry sector, 2016-2024
  • 2.3.4. Option and evaluation dealmaking by therapy area, 2016-2024
  • 2.3.5. Option and evaluation dealmaking by technology type, 2016-2024
  • 2.3.6. Option and evaluation dealmaking by most active company, 2016-2024
• 2.4. Reasons for entering into option and evaluation partnering deals
• 2.5. The future of option and evaluation deals

Chapter 3 - Overview of option and evaluation deal structure

• 3.1. Introduction
• 3.2. Option and evaluation agreement structure

Chapter 4 - Leading option and evaluation deals

• 4.1. Introduction
• 4.2. Top option and evaluation deals by value

Chapter 5 - Top 25 most active option and evaluation dealmakers

• 5.1. Introduction
• 5.2. Top 25 most active option and evaluation dealmakers

Chapter 6 - option and evaluation deals including contracts directory

• 6.1. Introduction
• 6.2. Option and evaluation deals with contracts 2016-2024
• Deal directory
• Deal directory - option and evaluation dealmaking by companies A-Z
• Deal directory - option and evaluation dealmaking by therapy area
• Deal directory - option and evaluation dealmaking by technology type

About Wildwood Ventures

• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

TABLE OF FIGURES

• Figure 1: Definition of option and evaluation
• Figure 2: Trends in option and evaluation deal announcements, 2016-2024
• Figure 3: Option and evaluation deals signed at each phase of development, 2016-2024
• Figure 4: Option and evaluation deals by industry sector, 2016-2024
• Figure 5: Option and evaluation deals by therapy area, 2016-2024
• Figure 6: Option and evaluation deals by technology type, 2016-2024
• Figure 7: Top 25 most active option and evaluation dealmakers, 2016-2024
• Figure 8: Top option and evaluation deals by value, 2016-2024
• Figure 9: Most active option and evaluation dealmakers, 2016-2024